Blueprint Medicines (BPMC) PT Raised to $125 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Matthew Biegler raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $125.00 (from $114.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
